Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Beijing Foyou Pharma Co., Ltd. on 6ix
Earlier from Beijing Foyou Pharma
- Announcement on Obtaining Drug Registration Certificate for Dydrogesterone Tablets
- Announcement on Obtaining Drug Registration Certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II)
- Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (15 mg/850 mg)
- Announcement on Obtaining Drug Registration Certificate for Arotinolol Hydrochloride Tablets
- Announcement on Obtaining Drug Registration Certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules
Later from Beijing Foyou Pharma
- Announcement on Proposed Selection in the 11th National Centralized Drug Procurement
- Announcement on Obtainment of the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets (I)
- Announcement on the Election of Employee Directors and the Adjustment of Audit Committee Members
- Announcement on Approval Notice for Clinical Trials of Ketoprofen Gel Patch
- Announcement on Completion of Industrial and Commercial Filing
Follow Beijing Foyou Pharma into a list and get an email when it puts out news.
Follow Beijing Foyou Pharma